ENGAGE-501; Phase II study investigating the role of epigenetic therapy with entinostat (SNDX-275) hi relapsed and refractory Hodgkin's lymphoma (HL)

被引：2
|
作者：
Younes, A.
Rosen, P. J.
Hernandez-Ilizaliturri, F. J.
Bociek, G.
Kasamon, Y. L.
Copeland, A.
Lee, G. T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Tower Canc Res Fdn, Beverly Hills, CA USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Univ Nebraska Med Ctr, Omaha, NE USA
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] Syndax Pharmaceut Inc, Waltham, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps298
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS298
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study
    Qualls, David
    Noy, Ariela
    Straus, David
    Matasar, Matthew
    Moskowitz, Craig
    Seshan, Venkatraman
    Dogan, Ahmet
    Salles, Gilles
    Younes, Anas
    Zelenetz, Andrew D.
    Batlevi, Connie Lee
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 738 - 741
  • [22] A Lysa Phase II Study of Oral JAK1/2 Inhibitor Ruxolitinib in Advanced Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)
    Van Den Neste, Eric W.
    Andre, Marc
    Gastinne, Thomas
    Stamatoullas, Aspasia
    Haioun, Corinne
    Belhabri, Amine
    Reman, Oumedaly
    Casasnovas, Olivier
    Ghesquieres, Herve
    Verhoef, Gregor
    Claessen, Marie-Jose
    Poirel, Helene A.
    Copin, Marie-Christine
    Dubois, Romain
    Vandenberghe, Peter
    Stoian, Ioanna-Andrea
    Cottereau, Anne Segolene
    Knoops, Laurent
    Morschhauser, Franck
    BLOOD, 2016, 128 (22)
  • [23] Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients
    Viviani, S.
    Bonfante, V.
    Fasola, C.
    Valagussa, P.
    Gianni, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: A phase II randomized study
    Tondini, C
    Balzarotti, M
    Rampinelli, I
    Valagussa, P
    Luoni, M
    De Paoli, A
    Santoro, A
    Bonadonna, G
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 231 - 233
  • [25] PHASE II STUDY OF THE HISTONE-DEACIETYLASE INHIBITOR ITF2357 IN RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA PATIENTS
    Bonfante, V.
    Viviani, S.
    Fasola, C.
    Crippa, F.
    Marchiano, A.
    Valagussa, P.
    Gianni, A. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 244 - 244
  • [26] Phase II study of denileukin diftitox (ONTAK) for relapsed/refractory T-cell non-Hodgkin's lymphoma
    Dang, NH
    Pro, B
    Fredrick, HR
    Samaniego, F
    Jones, D
    Rodriguez, M
    Goy, A
    Roaguera, J
    Walker, PL
    Younes, A
    Neelapu, S
    Kwak, L
    Fayad, L
    BLOOD, 2005, 106 (11) : 936A - 936A
  • [27] Results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma
    Witzig, Thomas E.
    Vose, Julie M.
    Moore, Timothy D.
    Reeder, Craig B.
    Cole, Craig E.
    Justice, Glen
    Kaplan, Henry P.
    Voralia, Michael
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Wiernik, Peter H.
    BLOOD, 2007, 110 (11) : 754A - 755A
  • [28] A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)
    Gribben, JG
    Bartlett, NL
    Stephenson, JJ
    Milder, MS
    Boccia, RV
    Redfern, C
    Mizuno, VM
    Berenson, RJ
    Frohlich, MW
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 76 - 76
  • [29] A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL)
    Gribben, JG
    Stephenson, JJ
    Bartlett, NL
    Milder, MS
    Boccia, RV
    Redfern, C
    Mizuno, VM
    Hillson, J
    Berenson, RJ
    Frohlich, MW
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 168S - 168S
  • [30] A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL).
    Bartlett, NL
    Gribben, JC
    Boccia, RV
    Milder, MS
    Aboulafia, DM
    Castro, J
    Flinn, I
    Hayes-Lattin, B
    Kaplan, L
    Lin, T
    Lucas, JB
    Maloney, DG
    McLaughlin, P
    McSweeney, PA
    Mohrbacher, A
    Redfern, C
    Steis, R
    Stephenson, JJ
    Strair, R
    Berenson, RJ
    Frohlich, MW
    BLOOD, 2004, 104 (11) : 244B - 244B
12345